TerminatedPhase 2

Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration

Stopped: undefined

Mexico25 participantsStarted 2006-03

Plain-language summary

The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.

Who can participate

Age range55 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: 55 years old neovascular Age related acular degeneration subfoveolar neovascular membrane best corrected visual acuity better than 20/200 snellen (1.0 logMAR) Exclusion Criteria: * Previously treated eyes glaucoma diabetes mellitus uncontrolled hypertension coronary artery disease

What they're measuring

Visual acuity improvement at 6 months

Timeframe: undefined

Trial details

NCT IDNCT00347399

SponsorAsociación para Evitar la Ceguera en México

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2006-06-30

View on ClinicalTrials.gov More Age Related Macular Degeneration trials